• Policy
• Boryung Zepzelca, conditional approval with phase 2 data
• by Lee, Hye-Kyung Sep 29, 2022 05:49am

• Company
• Daewoong Pharmaceutical SGLT-2 Diabetes New Envlo
• by Kim, Jin-Gu Sep 28, 2022 06:06am

• Company
• 4th JAKi Cibinqo makes a step towards reimbursement
• by Eo, Yun-Ho Sep 28, 2022 06:06am

• Company
• MFDS allows academic marketing of EUA COVID-19 treatments
• by Sep 28, 2022 06:05am

• Policy
• Janssen's Talquetamab, approved for Phase 3 in Korea
• by Lee, Hye-Kyung Sep 28, 2022 06:05am

• Company
• Reduce steroid in long-term use of Dupixent in asthmatic pts
• by Sep 28, 2022 06:05am

• Policy
• Generic for Acelex will be released
• by Lee, Tak-Sun Sep 27, 2022 05:51am

• Company
• MOHW's view of ‘few’ and ‘pediatric’ for PE exemptions
• by Eo, Yun-Ho Sep 27, 2022 05:51am

• Policy
• Hutecs targets pitavastatin market with its lowest-price
• by Lee, Tak-Sun Sep 27, 2022 05:51am

• Company
• Daewoong Nabota is expected to take a global leap
• by Nho, Byung Chul Sep 27, 2022 05:51am